249-443-3|Guanfacine Hydrochloride|N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride|-范德生物科技公司

Guanfacine Hydrochloride

NMR下载 COA and HPLC MSDS下载
names：
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide;hydrochloride
CAS号：
249-443-3
MDL Number：
MF(分子式)： C9H10Cl3N3O MW(分子量)： 282.55
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Guanfacine Hydrochloride
英文别名	Guanfacine Hydrochloride; BS 100 141; BS-100-141; BS100141; Estulic; Guanfacine; Guanfacine Hydrochloride; Guanfacine Monohydrochloride; Hydrochloride, Guanfacine; Lon798; Monohydrochloride, Guanfacine;
CAS号	249-443-3
Inchi	InChI=1S/C9H9Cl2N3O.ClH/c10-6-2-1-3-7(11)5(6)4-8(15)14-9(12)13;/h1-3H,4H2,(H4,12,13,14,15);1H
InchiKey	DGFYECXYGUIODH-UHFFFAOYSA-N
分子式 Formula	C9H10Cl3N3O
分子量 Molecular Weight	282.55
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Guanfacine Hydrochloride(CAS:249-443-3):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Guanfacine Hydrochloride is a centrally acting alpha-2 adrenergic agonist with antihypertensive activity. Alpha-2 receptor stimulation by guanfacine hydrochloride results in a decreased sympathetic outflow from the vasomotor center to the heart, kidneys, and peripheral vasculature. This leads to a decrease in heart rate and peripheral vascular resistance.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, Ramos-Quiroga JA,van Stralen J, Dutray B, Sreckovic S, Bloomfield R, Robertson B. Extended-releaseguanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawalmaintenance of efficacy study. J Child Psychol Psychiatry. 2016 Feb 12. doi:10.1111/jcpp.12492. [Epub ahead of print] PubMed PMID: 26871297.

[2]Butterfield ME, Saal J, Young B, Young JL. Supplementary guanfacinehydrochloride as a treatment of attention deficit hyperactivity disorder inadults: A double blind, placebo-controlled study. Psychiatry Res. 2016 Feb28;23

6:136-41. doi: 10.1016/j.psychres.2015.12.017. Epub 2015 Dec 17. PubMedPMID: 26730446.

[4]Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A,Bloomfield R, Sikirica V, Robertson B. Efficacy and safety of extended-releaseguanfacine hydrochloride in children and adolescents withattention-deficit/hyperactivity disorder: a randomized, controlled, phase IIItrial. Eur Neuropsychopharmacol. 2014 Dec;24(12):1861-72. doi:10.1016/j.euroneuro.2014.09.014. Epub 2014 Oct 23. PubMed PMID: 25453486.

[5] Board AW, Perry VP, Shepperson BE, Nyman CE, Carchman SH. A postmarketingevaluation of guanfacine hydrochloride in mild to moderate hypertension. ClinTher. 1988;10(6):761-75. PubMed PMID: 3064907.

5: Yamadera H, Ferber G, Matejcek M, Pokorny R. Electroencephalographic andpsychometric assessment of the CNS effects of single doses of guanfacinehydrochloride (Estulic) and clonidine (Catapres). Neuropsychobiology.1985;14(2):97-107. PubMed PMID: 3911096.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开